Chungming Fu

Dr. Chungming Fu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2024 in Medicina
Verified
Journal Article
Open access
PDF file
FLFOONG-FAH LEONG
FOONG-FAH LEONG
Wen-Chin LeeWen-Chin Lee
Wen-Chin Lee
HNHwee-Yeong Ng
Hwee-Yeong Ng
PKPo-Yen Kuo
Po-Yen Kuo
CLChien-Te Lee
Chien-Te Lee
CFChungming Fu
Chungming Fu
Background and Objectives: Vascular access complications, particularly high venous pressure, pose significant challenges for hemodialysis patients undergoing hemodialysis. Limited research has focused on identifying predictive factors for invasive treatment. This study aimed to identify patients who might benefit from frequent monitoring and conservative management based on duplex ultrasound (DUS) evaluation. Materials and Methods: This retrospective study included 72 hemodialysis patients with high venous pressure who underwent DUS. Patients were divided into conservative (n = 26) and invasive treatment groups (n = 46). Key factors such as flow/pressure ratio, blood flow, and venous pressure were analyzed. Logistic regression was used to identify risk factors for invasive treatment, while receiver operating characteristic (ROC) analysis was performed to establish the optimal cutoff for the flow/pressure ratio. Results: Three months after the DUS, 3.85% of the conservative group experienced access failure, compared to 71.7% in the invasive group. The flow/pressure ratio was significantly lower in the invasive group (1.28 ± 0.26 vs. 1.47 ± 0.23, p < 0.05). A higher flow/pressure ratio (OR: 0.063, 95% CI: 0.004–0.932, p = 0.044) and the presence of tortuous veins (OR: 0.080, 95% CI: 0.007–0.897, p = 0.0405) were associated with a lower risk of invasive treatment. ROC analysis showed a flow/pressure ratio cutoff of 1.38 (AUC: 0.706, p = 0.004). Conclusions: Duplex ultrasound plays a crucial role in evaluating arterio-venous access in patients with high venous pressure. It provides a non-invasive assessment of vascular complications, helping avoid unnecessary invasive procedures. The flow/pressure ratio is significantly associated with the risk of invasive treatment, providing a valuable threshold for assessing risk and guiding clinical decision-making to optimize treatment strategies.

22 September 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YLYi-Chen Li
Yi-Chen Li
JHJui-Ting Hsu
Jui-Ting Hsu
CFChungming Fu
Chungming Fu
TLTing-Chun Liu
Ting-Chun Liu
YLYueh-Ting Lee
Yueh-Ting Lee
CYChih-Chao Yang
Chih-Chao Yang
Background: Peritoneal dialysis (PD) is an established kidney replacement therapy, but long-term exposure to bioincompatible dialysate, uremic toxins, recurrent peritonitis, glucose degradation products, oxidative stress, and sterile inflammation progressively remodels the peritoneal membrane and contributes to peritoneal fibrosis (PF). This review summarizes the molecular basis of PF in PD and evaluates the therapeutic rationale for incretin-based interventions beyond weight loss and glycemic control. Methods: This narrative review synthesizes mechanistic, translational, and clinically relevant literature on PD-associated PF, with emphasis on DPP-4 biology, GLP-1 receptor agonism, inflammatory and oxidative signaling, angiogenesis, mesothelial-to-mesenchymal transition, glycemic management in PD, and selected author-conducted translational studies interpreted alongside independent evidence. Results: Available evidence supports a model in which DPP-4 activation, altered GLP-1/GLP-1R signaling, TGF-β/Smad3-driven mesothelial transition, NF-κB/MyD88 inflammation, ROS-mediated oxidative stress, angiogenesis, apoptosis, and cytoskeletal remodeling converge to impair peritoneal membrane integrity. DPP-4 inhibition, exendin-4, and dulaglutide attenuated these pathways in experimental models, while GLP-1 receptor agonists have established metabolic benefits in appropriate diabetic and obese populations. Conclusions: Direct clinical evidence that incretin-based therapies prevent or treat peritoneal fibrosis in humans undergoing PD is currently lacking. Therefore, peritoneal membrane protection, reduced ultrafiltration failure, and improved technique survival should be regarded as investigational, hypothesis-generating possibilities that require prospective clinical validation.